Groundbreaking Blood Filtration Technique Extends Pregnancy for Women Facing Severe Early Preeclampsia Risks

Medical researchers develop a filtration technique to remove toxic proteins, safely extending pregnancy for women with severe early preeclampsia symptoms.

By: AXL Media

Published: Apr 28, 2026, 6:09 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Vital Window for Neonatal Development

Medical professionals at Cedars-Sinai Health Sciences University have pioneered a clinical intervention that addresses the immediate dangers of early onset preeclampsia, a condition that often forces a choice between maternal safety and infant maturity. By targeting a specific protein in the mother's bloodstream, researchers have found a way to stabilize blood pressure and maintain the pregnancy longer than previously possible. According to Ananth Karumanchi, MD, a professor at Cedars-Sinai, even a minimal extension of time within the womb can lead to substantially better health outcomes for babies born before the 34 week mark.

The Mechanical Extraction of Placental Toxins

The therapeutic mechanism centers on the removal of sFlt-1, a protein generated by the placenta that is known to cause systemic vascular damage in the mother. Rather than utilizing traditional pharmaceutical agents that may carry secondary risks, the team employed a method known as extracorporeal apheresis, which functions similarly to the dialysis used for kidney failure. This process utilizes an engineered immune protein to bind with and extract the harmful sFlt-1 without depleting other vital components of the patient's blood. This targeted filtration allows for a reduction in the biological drivers of the disease while keeping the circulatory system otherwise intact.

Clinical Validation Through Pilot Testing

A group of 16 women participated in the early stage trial, which yielded results that suggest a significant shift in how the condition might be managed. During the course of the treatment, the subjects experienced improved blood pressure readings while fetal growth remained within normal parameters. On average, the intervention allowed participants to remain pregnant for ten additional days, a duration that is more than double the timeframe observed in patients who do not receive this specialized care. Sarah Kilpatrick, MD, PhD, noted that this approach offers clinicians much needed flexibility, as the only current cure for the condition is the immediate delivery of the infant.